# FDA Approves ANDA for Steranco Healthcare Steranco Healthcare has received FDA approval for an abbreviated new drug application (ANDA220281), positioning the company to expand its generic pharmaceutical portfolio and capture additional market share in the competitive generic drug sector. The approval strengthens Steranco's competitive standing and could drive near-term revenue growth as the company moves toward commercialization of the newly approved product.